The Cladribine market is gaining traction globally, driven by its increasing use in treating multiple sclerosis (MS) and certain cancers such as hairy cell leukemia. Cladribine, a synthetic purine nucleoside analogue, disrupts DNA synthesis in rapidly dividing cells, making it an effective treatment for these proliferative conditions. Originally approved for hematologic cancers, Cladribine has...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian